June 30, 2020

COVAXIN, India’s first vaccine candidate against novel coronavirus, developed by vaccine maker Bharat Biotech gets the approval of Drug Controller General of India (DCGI) for Phase I and II clinical trials.


  • COVAXIN is an inactivated vaccine, created from a strain of the infectious SARS-CoV-2 virus, that has shown promise in preclinical studies, demonstrating extensive safety and effective immune responses.

  • COVAXIN has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

  • The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine will be developed and manufactured by Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

  • Human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020. 

Source : Times Now